2025年Biomedtracker和Datamonitor Healthcare ASH会后报告

December2025 Summary Biomedtracker and Datamonitor Healthcare present the post-report for the 67th Annual Meeting of the AmericanSocietyofHematology(ASH)heldinSanDiego,CaliforniafromDecember6-9,2025.Conferencehighlightsinclude: FLT3inhibitorcrenolanibdemonstratesnichebenefitsatASH2025inrelapsed/refractoryAMLpatientsKomzifticontinuestodemonstratecompetitiveefficacyandsafetywithpositiveinitialPhaseItrialresultsOlverembatinibdemonstratesimpressiveMRD-negativityratesinuntreatedPh+ALL,settingupFDAandEMAclearance Thispost-meetingreportfeaturescommentaryfromouranalystsonspecificpresentations.Italsoincludesacompilationofall data events added in conjunction with the meeting. AbouttheAuthor Biomedtrackeris an independent research service that offers proprietary clinical assessments and patient-based revenueforecasts of developmental drugs within a comprehensive and intuitive drug information database. Clients from thepharmaceutical, biotech, and investment industries rely on Biomedtracker for its insight on the likelihood of approval,commercialpotential,andfuturedataandregulatorycatalystsfordrugswithinthecompetitive landscapeof every importantdisease and indication. Over the last several years, Biomedtracker has become the leader in providing objective informationalongsideevidencebasedclinicalassessmentsandinvestmentresearchonpipelinedrugsworldwide.Formoreinformationongetting direct access to Biomedtracker, please emailclientservices@citeline.com. Disclaimer Copyright©2025PharmaIntelligence UK Limited(Citeline),a Norstellacompany This report is published by Citeline (the Publisher). This report contains information from reputable sources and althoughreasonable efforts have been made to publish accurate information, you assume sole responsibility for the selection,suitabilityanduseofthisreportand acknowledgethat thePublishermakesnowarranties(eitherexpressor implied) as to, nor acceptsliability for, the accuracy or fitnessfor aparticularpurpose of theinformationor advice contained herein. ThePublisherwishestomakeitclearthatanyviewsoropinionsexpressedinthisreportbyindividualauthorsorcontributorsaretheirpersonalviewsand opinions and do not necessarily reflectthe views/opinions of the Publisher. OLVEREMBATINIBFORACUTELYMPHOBLASTICLEUKEMIA(ALL)……………………………….………………………………….…………….4KOMZIFTIFORACUTEMYELOGENOUSLEUKEMIA(AML)……………………………………….………………………………………….…………8VENCLEXTAFORACUTEMYELOGENOUSLEUKEMIA(AML)……………………………………………………….……………………….……..11CRENOLANIBFORACUTEMYELOGENOUSLEUKEMIA(AML)………………………………………………….…………………………………..14BEXOBRUTIDEGFORCHRONICLYMPHOCYTICLEUKEMIA(CLL)/SMALLCELL LYMPHOCYTIC LYMPHOMA (SLL)–NHL…18BGB-16673FORCHRONICLYMPHOCYTICLEUKEMIA(CLL)/SMALLCELL LYMPHOCYTIC LYMPHOMA (SLL)–NHL………..22TERN-701FORCHRONICMYELOGENOUSLEUKEMIA(CML)…………………………………………………………………….…………………..25OLVEREMBATINIBFORCHRONICMYELOGENOUSLEUKEMIA(CML)…………………………………………………………………………….29NXT007FORHEMOPHILIAA……………………………………………………………………………………………………………………………………….32GLPG5101FORMANTLECELLLYMPHOMA–NHL………………………………………………………………………………………………………..35BEZUCLASTINIBFORMASTOCYTOSIS………………………………………………………………………………………………………………………….38TECVAYLIFORMULTIPLEMYELOMA(MM)………………………………………………………………………………………………………………….42CCS1477FORMULTIPLEMYELOMA(MM)…………………………………………………………………………………………………………………..45RYTELOFORMYELODYSPLASTICSYNDROME(MDS)…………………………………………………………………………………………………….48ELRITERCEPTFORMYELODYSPLASTICSYNDROME(MDS)…………………………………………………………………………………………….51RUSFERTIDEFORPOLYCYTHEMIAVERA(PV)……………………………………………………………………………………………………………….54LIST OF BIOMEDTRACKER ASH 2024 EVENTS......................................................................................................................57 AscentagePharmaannouncedthatit haspresentedthefirst datasetfromtheglobal registrationalPhaseIIIstudy(POLARIS-1)ofthecompany’snovel,investigationaldrug,Olverembatinib(HQP1351),incombinationwithlow-intensitychemotherapyinpatientswithnewly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), in a poster presentation at the 67thAmerican Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida.The abstract entitled “Results ofPOLARIS-1, a global Phase III study (Part A): Olverembatinib combined with low intensity chemotherapy in patients with newlydiagnosed(ND)Philadelphiachromosome-positive(Ph+)acutelymphoblasticleukemia(ALL)”waspresentedonDecember6,2025. Context First dataset from the global registrational Phase III POLARIS-1 study of olverembatinib in combination with low-intensitychemotherapyfornewlydiagnosedPhiladelphiachromosome-positiveacutelymphoblasticleukemia;thetrialwasrecentlyclearedbythe U.S. Food and Drug Administration and European Medicines Agency, and the company has an exclusive option agreement withTakeda for ex-China rights. Design Global,registrationalPhaseIIIstudyevaluatingolverembatinibcombinedwithlow-intensitychemotherapyinpatientswithnewlydiagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Endpoints Primaryendpoint:minim